Merck Signs Second Deal With Addex | Chemical & Engineering News
Volume 86 Issue 1 | p. 12 | Concentrates
Issue Date: January 7, 2008

Merck Signs Second Deal With Addex

Department: Business

Merck & Co. has signed a second drug development deal with the Swiss biotech firm Addex Pharmaceuticals. Under an exclusive license agreement, the two firms will develop Addex ADX63365, an orally available allosteric modulator now in preclinical development for the treatment of schizophrenia. Addex will get $22 million upfront and is eligible for up to $455 million in milestone payments. Last month the two launched an allosteric modulator collaboration focused initially on Parkinson's disease.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment